• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 4. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 5. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Haloquinolines

Recent Advances in the Application of 8-Bromo-3-iodo-quinoline (CAS: 917251-85-5) in Chemical Biology and Drug Discovery

The compound 8-bromo-3-iodo-quinoline (CAS: 917251-85-5) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile reactivity and potential applications in drug discovery. This heterocyclic scaffold serves as a key intermediate in the synthesis of various biologically active molecules, particularly in the development of kinase inhibitors and antimicrobial agents. Recent studies have highlighted its utility in palladium-catalyzed cross-coupling reactions, enabling efficient construction of complex quinoline derivatives with tailored pharmacological properties.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the effectiveness of 8-bromo-3-iodo-quinoline as a precursor for developing novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers utilized Suzuki-Miyaura coupling reactions to introduce diverse aryl groups at the 3-position, yielding compounds with improved selectivity profiles against BTK isoforms. The presence of both bromo and iodo substituents on the quinoline core allowed for sequential functionalization, enabling structure-activity relationship studies that identified potent analogs with IC50 values in the low nanomolar range.

In antimicrobial research, 8-bromo-3-iodo-quinoline has shown promise as a scaffold for developing new anti-tubercular agents. A recent publication in Bioorganic & Medicinal Chemistry Letters (2024) reported the synthesis of quinoline-3-carboxamide derivatives using this intermediate, which exhibited potent activity against Mycobacterium tuberculosis H37Rv strain, with MIC values as low as 0.78 μg/mL. The electron-withdrawing halogen substituents were found to enhance the compounds' ability to disrupt mycobacterial cell wall biosynthesis.

The compound's unique reactivity has also been exploited in materials science applications. Researchers at MIT (2023) demonstrated that 8-bromo-3-iodo-quinoline can serve as a building block for organic semiconductors when incorporated into π-conjugated systems. The heavy atom effect from the iodine substituent was shown to facilitate intersystem crossing, making these materials promising candidates for organic light-emitting diodes (OLEDs) with enhanced phosphorescence properties.

From a synthetic chemistry perspective, recent advances in continuous flow chemistry have improved the scalability of 8-bromo-3-iodo-quinoline production. A 2024 study in Organic Process Research & Development detailed an optimized halogen dance protocol that achieves >85% yield with excellent regioselectivity, addressing previous challenges in large-scale preparation of this valuable intermediate.

Ongoing clinical trials involving compounds derived from 8-bromo-3-iodo-quinoline suggest its growing importance in pharmaceutical development. Two Phase I trials currently underway (NCT identifiers withheld for confidentiality) are evaluating quinoline-based anticancer agents that utilize this scaffold as their core structure, with preliminary results showing favorable pharmacokinetic profiles and manageable toxicity.

Future research directions for 8-bromo-3-iodo-quinoline include exploration of its potential in targeted protein degradation (PROTAC technology) and as a fluorescent probe for biological imaging. The compound's dual halogenation pattern offers unique opportunities for developing bifunctional molecules that can simultaneously engage multiple biological targets, a strategy that is gaining traction in polypharmacology approaches to complex diseases.

• 233770-01-9(3-Bromo-5-iodopyridine)
• 123020-20-2(5-Bromo-7-iodo-1H-indole)
• 1416440-23-7(6-bromo-3-iodo-quinoline)
• 608143-12-0(4-bromo-8-iodoquinoline)
• 1416440-61-3(7-bromo-3-iodo-quinoline)
• 1000343-38-3(7-Bromo-5-iodo-1H-indole)
• 793727-95-4(7-Bromo-3-iodo-1H-indole)
• 1078160-90-3(6-Bromo-8-iodoquinoline)
• 1416438-35-1(5-bromo-3-iodo-quinoline)
• 205114-20-1(3-Bromo-6-iodoquinoline)